Who is sponsoring NCT05211193?

NCT05211193 is sponsored by Stimvia s.r.o..

What drugs are being tested in NCT05211193?

Interventions in NCT05211193: eTNM delivered by URIS I nerve stimulation device.

What condition does NCT05211193 study?

NCT05211193 studies Overactive Bladder (OAB), Failed Any OAB Pharmacotherapy.

Is NCT05211193 still recruiting?

NCT05211193 is currently completed. Last updated 17 February 2022.

Last reviewed 2022-02-17 · How we verify

NCT05211193

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).

Completed Last updated 17 February 2022

What this trial tests

trial testing eTNM delivered by URIS I nerve stimulation device in Overactive Bladder (OAB) in 40 participants. Completed in 2 November 2020.

Timeline

8 January 2020

Primary endpoint
28 April 2020

2 November 2020

Quick facts

Lead sponsor	Stimvia s.r.o.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	8 January 2020
Primary completion	28 April 2020
Estimated completion	2 November 2020
Sites	1 location across Czechia

Drugs / interventions tested

eTNM delivered by URIS I nerve stimulation device

Conditions studied

Overactive Bladder (OAB) — all drugs for Overactive Bladder (OAB) →
Failed Any OAB Pharmacotherapy — all drugs for Failed Any OAB Pharmacotherapy →

Sponsor

Stimvia s.r.o.

Who can join

18 and older, female only, with Overactive Bladder (OAB) or Failed Any OAB Pharmacotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous NeuroModulation (eTNM) Treatment Via Nerve Stimulator URIS I in the Treatment of Overactive Bladder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder (OAB)

Currently open trials in the same condition.

NCT07193407 — INOPASE - Performance and Safety Study of a Personalised SNM System · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT07195656 — Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) · NA · recruiting
NCT07025044 — Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrus · recruiting
NCT07371000 — Early Detection of OAB and Elimination of Negative Impact on Quality of Life · NA · recruiting

Other Stimvia s.r.o. trials

Trials by the same sponsor.

NCT06036368 — Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease an · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05211193 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stimvia s.r.o.
Last refreshed: 17 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05211193.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing